

Renato Delascio Lopes

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8617016/publications.pdf>

Version: 2024-02-01

365
papers

28,649
citations

11639

70
h-index

5986

160
g-index

372
all docs

372
docs citations

372
times ranked

25590
citing authors

#	ARTICLE	IF	CITATIONS
1	Association of Non-Alcoholic Fatty Liver Disease With in-Hospital Outcomes in Primary Heart Failure Hospitalizations With Reduced or Preserved Ejection Fraction. <i>Current Problems in Cardiology</i> , 2023, 48, 101199.	1.1	12
2	Risk of stroke and bleeding in relation to hypertension in anticoagulated patients with atrial fibrillation: a meta-analysis of randomised controlled trials. <i>Acta Cardiologica</i> , 2022, 77, 191-195.	0.3	8
3	Antiplatelet therapy in patients with atrial fibrillation: a systematic review and meta-analysis of randomized trials. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2022, 8, 648-659.	1.4	11
4	Using multimarker screening to identify biomarkers associated with cardiovascular death in patients with atrial fibrillation. <i>Cardiovascular Research</i> , 2022, 118, 2112-2123.	1.8	18
5	Global representation of heart failure clinical trial leaders, collaborators, and enrolled participants: a bibliometric review 2000â€“20. <i>European Heart Journal Quality of Care & Clinical Outcomes</i> , 2022, 8, 659-669.	1.8	13
6	Safety and efficacy of different prophylactic anticoagulation dosing regimens in critically and non-critically ill patients with COVID-19: a systematic review and meta-analysis of randomized controlled trials. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2022, 8, 677-686.	1.4	45
7	Heterogeneity of diabetes as a risk factor for major adverse cardiovascular events in anticoagulated patients with atrial fibrillation: an analysis of the ARISTOTLE trial. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2022, 8, 227-235.	1.4	6
8	Non-Vitamin K Antagonists Versus Warfarin in Patients with Atrial Fibrillation and Bioprosthetic Valves: A Systematic Review and Meta-Analysis. <i>American Journal of Medicine</i> , 2022, 135, 228-234.e1.	0.6	4
9	Cluster Analysis of Cardiovascular Phenotypes in Patients With Type 2 Diabetes and Established Atherosclerotic Cardiovascular Disease: A Potential Approach to Precision Medicine. <i>Diabetes Care</i> , 2022, 45, 204-212.	4.3	25
10	Efpeglenatide and Clinical Outcomes With and Without Concomitant Sodium-Glucose Cotransporter-2 Inhibition Use in Type 2 Diabetes: Exploratory Analysis of the AMPLITUDE-O Trial. <i>Circulation</i> , 2022, 145, 565-574.	1.6	59
11	Direct Oral Anticoagulants Versus Warfarin in Patients With Atrial Fibrillation: Patient-Level Network Meta-Analyses of Randomized Clinical Trials With Interaction Testing by Age and Sex. <i>Circulation</i> , 2022, 145, 242-255.	1.6	118
12	Effect of P2Y12 Inhibitors on Survival Free of Organ Support Among Nonâ€“Critically Ill Hospitalized Patients With COVID-19. <i>JAMA - Journal of the American Medical Association</i> , 2022, 327, 227.	3.8	89
13	Ischemic Events Occur Early in Patients Undergoing Percutaneous Coronary Intervention and Are Reduced With Cangrelor: Findings From CHAMPION PHOENIX. <i>Circulation: Cardiovascular Interventions</i> , 2022, 15, CIRCINTERVENTIONS120010390.	1.4	4
14	Rivaroxaban versus no anticoagulation for post-discharge thromboprophylaxis after hospitalisation for COVID-19 (MICHELLE): an open-label, multicentre, randomised, controlled trial. <i>Lancet, The</i> , 2022, 399, 50-59.	6.3	172
15	Estimated incidence of previously undetected atrial fibrillation on a 14-day continuous electrocardiographic monitor and associated risk of stroke. <i>Europace</i> , 2022, , .	0.7	13
16	Antithrombotic Therapy in Patients With Atrial Fibrillation After Acute Coronary Syndromes or Percutaneous Intervention. <i>Journal of the American College of Cardiology</i> , 2022, 79, 417-427.	1.2	12
17	Clinical events classification (CEC) in clinical trials: Report on the current landscape and future directions â€” proceedings from the CEC Summit 2018. <i>American Heart Journal</i> , 2022, 246, 93-104.	1.2	3
18	Efficacy and safety of sodium-glucose cotransporter 2 inhibitors initiation in patients with acute heart failure, with and without type 2 diabetes: a systematic review and meta-analysis. <i>Cardiovascular Diabetology</i> , 2022, 21, 20.	2.7	36

#	ARTICLE	IF	CITATIONS
19	Relationship between ventricular repolarization parameters and the inducibility of ventricular arrhythmias during electrophysiological study in patients with coronary artery disease. <i>Revista Da Associação Médica Brasileira</i> , 2022, 68, 61-66.	0.3	0
20	Risk Scores in Acute Coronary Syndrome: Current Applications and Future Perspectives. <i>International Journal of Cardiovascular Sciences</i> , 2022, 35, 181-183.	0.0	0
21	Non-vitamin K antagonist oral anticoagulants in patients with valvular heart disease. <i>European Heart Journal Supplements</i> , 2022, 24, A19-A31.	0.0	6
22	Diagnosis and Treatment of Acute Coronary Syndromes. <i>JAMA - Journal of the American Medical Association</i> , 2022, 327, 662.	3.8	219
23	The Anti-Coronavirus Therapies (ACT) Trials: Design, Baseline Characteristics, and Challenges. <i>CJC Open</i> , 2022, 4, 568-576.	0.7	4
24	Effect of Platelet Inhibition by Cangrelor Among Obese Patients Undergoing Coronary Stenting: Insights From CHAMPION. <i>Circulation: Cardiovascular Interventions</i> , 2022, 15, CIRCINTERVENTIONS121011069.	1.4	0
25	Commissioned Commentary on the 2021 American Society of Hematology Guidelines on use of anticoagulation in patients with COVID-19 being discharged from the hospital. <i>Blood Advances</i> , 2022, , .	2.5	1
26	Sodium-Glucose Cotransporter 2 Inhibitors and Cardiac Remodeling. <i>Journal of Cardiovascular Translational Research</i> , 2022, 15, 944-956.	1.1	21
27	Effect of Alirocumab on Incidence of Atrial Fibrillation After Acute Coronary Syndromes: Insights from the ODYSSEY OUTCOMES Randomized Trial. <i>American Journal of Medicine</i> , 2022, , .	0.6	0
28	Discontinuing vs continuing ACEIs and ARBs in hospitalized patients with COVID-19 according to disease severity: Insights from the BRACE CORONA trial. <i>American Heart Journal</i> , 2022, 249, 86-97.	1.2	8
29	Independence of clinical events committees: A consensus statement from clinical research organizations. <i>American Heart Journal</i> , 2022, 248, 120-129.	1.2	2
30	Associated factors and clinical outcomes in mechanical circulatory support use in patients undergoing high risk on-pump cardiac surgery: Insights from the LEVO-CTS trial. <i>American Heart Journal</i> , 2022, 248, 35-41.	1.2	0
31	Hydroxychloroquine versus placebo in the treatment of non-hospitalised patients with COVID-19 (COPE – Coalition V): A double-blind, multicentre, randomised, controlled trial. <i>The Lancet Regional Health Americas</i> , 2022, 11, 100243.	1.5	11
32	Reducing stroke by screening for Undiagnosed atrial fibrillation in elderly individuals (GUARD-AF): Rationale and Design of the GUARD-AF Randomized Trial of Screening for Atrial Fibrillation with a 14-day Patch-Based Continuous ECG Monitor. <i>American Heart Journal</i> , 2022, 249, 76-76.	1.2	3
33	Apixaban or Warfarin and Aspirin or Placebo After Acute Coronary Syndrome or Percutaneous Coronary Intervention in Patients With Atrial Fibrillation and Prior Stroke. <i>JAMA Cardiology</i> , 2022, 7, 682.	3.0	3
34	Efficacy and Safety Considerations With Dose-Reduced Direct Oral Anticoagulants. <i>JAMA Cardiology</i> , 2022, 7, 747.	3.0	15
35	Good practice statements for antithrombotic therapy in the management of COVID-19: Guidance from the SSC of the ISTH. <i>Journal of Thrombosis and Haemostasis</i> , 2022, 20, 2226-2236.	1.9	23
36	Myocardial Infarction in the ISCHEMIA Trial. <i>Circulation</i> , 2021, 143, 790-804.	1.6	81

#	ARTICLE	IF	CITATIONS
37	Association between levosimendan, postoperative AKI, and mortality in cardiac surgery: Insights from the LEVO-CTS trial. <i>American Heart Journal</i> , 2021, 231, 18-24.	1.2	12
38	Sotagliflozin in Patients with Diabetes and Recent Worsening Heart Failure. <i>New England Journal of Medicine</i> , 2021, 384, 117-128.	13.9	1,080
39	Sotagliflozin in Patients with Diabetes and Chronic Kidney Disease. <i>New England Journal of Medicine</i> , 2021, 384, 129-139.	13.9	662
40	Individual Patient Data from the Pivotal Randomized Controlled Trials of Non-Vitamin K Antagonist Oral Anticoagulants in Patients with Atrial Fibrillation (COMBINE AF): Design and Rationale. <i>American Heart Journal</i> , 2021, 233, 48-58.	1.2	11
41	Anticoagulation dosing in atherosclerotic cardiovascular disease: Is less more?. <i>European Journal of Internal Medicine</i> , 2021, 83, 8-9.	1.0	0
42	Safety and efficacy of double vs. triple antithrombotic therapy in patients with atrial fibrillation with or without acute coronary syndrome undergoing percutaneous coronary intervention: a collaborative meta-analysis of non-vitamin K antagonist oral anticoagulant-based randomized clinical trials. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2021, 7, f50-f60.	1.4	24
43	Premature permanent discontinuation of apixaban or warfarin in patients with atrial fibrillation. <i>Heart</i> , 2021, 107, 713-720.	1.2	8
44	Antithrombotic Regimens in Low-Risk Patients Undergoing Transcatheter Aortic Valve Replacement. <i>Circulation: Cardiovascular Interventions</i> , 2021, 14, e010331.	1.4	0
45	Pregnancy-Associated Venous Thromboembolism: Insights from GARFIELD-VTE. <i>TH Open</i> , 2021, 05, e24-e34.	0.7	16
46	Gaps in Evidence-Based Therapy Use in Insured Patients in the United States With Type 2 Diabetes Mellitus and Atherosclerotic Cardiovascular Disease. <i>Journal of the American Heart Association</i> , 2021, 10, e016835.	1.6	31
47	Effect of Discontinuing vs Continuing Angiotensin-Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers on Days Alive and Out of the Hospital in Patients Admitted With COVID-19. <i>JAMA - Journal of the American Medical Association</i> , 2021, 325, 254.	3.8	299
48	Galectina-3 Associada a Formas Graves e Mortalidade em Longo Prazo em Pacientes com Doença de Chagas. <i>Arquivos Brasileiros De Cardiologia</i> , 2021, 116, 248-256.	0.3	9
49	Antithrombotic Strategies in Patients With Atrial Fibrillation and Percutaneous Coronary Intervention—Reply. <i>JAMA Cardiology</i> , 2021, 6, 241.	3.0	0
50	Antithrombotic Therapy in Patients With Atrial Fibrillation Treated With Oral Anticoagulation Undergoing Percutaneous Coronary Intervention. <i>Circulation</i> , 2021, 143, 583-596.	1.6	119
51	Response to: The paradox of implantable cardioverter-defibrillator: When guidelines play against care improvement. <i>American Heart Journal</i> , 2021, 233, 151-152.	1.2	0
52	Association of the left common ostium with clinical outcome after pulmonary vein isolation in atrial fibrillation. <i>Indian Pacing and Electrophysiology Journal</i> , 2021, 21, 95-100.	0.3	4
53	Apixaban or Vitamin K Antagonists and Aspirin or Placebo According to Kidney Function in Patients With Atrial Fibrillation After Acute Coronary Syndrome or Percutaneous Coronary Intervention. <i>Circulation</i> , 2021, 143, 1215-1223.	1.6	9
54	Effects of sodium-glucose cotransporter 1 and 2 inhibitors on cardiovascular and kidney outcomes in type 2 diabetes: A meta-analysis update. <i>American Heart Journal</i> , 2021, 233, 86-91.	1.2	38

#	ARTICLE	IF	CITATIONS
55	Apixaban Versus Warfarin in Patients With Atrial Fibrillation and Left Ventricular Hypertrophy. <i>Circulation: Arrhythmia and Electrophysiology</i> , 2021, 14, e009614.	2.1	1
56	Renal denervation for the treatment of ventricular arrhythmias: A systematic review and meta-analysis. <i>Journal of Cardiovascular Electrophysiology</i> , 2021, 32, 1430-1439.	0.8	3
57	Response by Lopes et al to Letter Regarding Article, "Initial Invasive Versus Conservative Management of Stable Ischemic Heart Disease Patients With a History of Heart Failure or Left Ventricular Dysfunction: Insights From the ISCHEMIA Trial". <i>Circulation</i> , 2021, 143, e961-e962.	1.6	0
58	Clinical and Economic Outcomes Among Nonvalvular Atrial Fibrillation Patients With Coronary Artery Disease and/or Peripheral Artery Disease. <i>American Journal of Cardiology</i> , 2021, 148, 69-77.	0.7	3
59	Therapeutic versus prophylactic anticoagulation for patients admitted to hospital with COVID-19 and elevated D-dimer concentration (ACTION): an open-label, multicentre, randomised, controlled trial. <i>Lancet, The</i> , 2021, 397, 2253-2263.	6.3	366
60	Incorporating SGLT2i and GLP-1RA for Cardiovascular and Kidney Disease Risk Reduction: Call for Action to the Cardiology Community. <i>Circulation</i> , 2021, 144, 74-84.	1.6	34
61	The association between cardiac intensive care unit mechanical ventilation volumes and in-hospital mortality. <i>European Heart Journal: Acute Cardiovascular Care</i> , 2021, 10, 797-805.	0.4	7
62	Assessment of North American Clinical Research Site Performance During the Start-up of Large Cardiovascular Clinical Trials. <i>JAMA Network Open</i> , 2021, 4, e2117963.	2.8	5
63	Diretrizes da Sociedade Brasileira de Cardiologia sobre Angina Instável e Infarto Agudo do Miocárdio sem Supradesnível do Segmento ST. 2021. <i>Arquivos Brasileiros De Cardiologia</i> , 2021, 117, 181-264.	0.3	45
64	Effect of Sotagliflozin on Total Hospitalizations in Patients With Type 2 Diabetes and Worsening Heart Failure. <i>Annals of Internal Medicine</i> , 2021, 174, 1065-1072.	2.0	32
65	Randomized clinical trial to evaluate a routine full anticoagulation Strategy in Patients with Coronavirus Infection (SARS-CoV2) admitted to hospital: Rationale and design of the ACTION (AntiCoagulation Coronavirus) Coalition IV trial. <i>American Heart Journal</i> , 2021, 238, 1-11.	1.2	19
66	Rivaroxaban for extended thromboprophylaxis in acutely ill medical patients 75 years of age or older. <i>Journal of Thrombosis and Haemostasis</i> , 2021, 19, 2772-2780.	1.9	4
67	Cardiovascular Safety of Degarelix Versus Leuprolide in Patients With Prostate Cancer: The Primary Results of the PRONOUNCE Randomized Trial. <i>Circulation</i> , 2021, 144, 1295-1307.	1.6	75
68	Clinical Phenotypes in Patients With Type 2 Diabetes Mellitus: Characteristics, Cardiovascular Outcomes and Treatment Strategies. <i>Current Heart Failure Reports</i> , 2021, 18, 253-263.	1.3	6
69	Posicionamento sobre Diagnóstico e Tratamento da Amiloidose Cardíaca. 2021. <i>Arquivos Brasileiros De Cardiologia</i> , 2021, 117, 561-598.	0.3	35
70	Cardiovascular and Renal Outcomes with Efglenatide in Type 2 Diabetes. <i>New England Journal of Medicine</i> , 2021, 385, 896-907.	13.9	339
71	Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of randomised trials. <i>Lancet Diabetes and Endocrinology</i> , 2021, 9, 653-662.	5.5	437
72	High risk coronavirus disease 2019: The primary results of the CoronaHeart multi-center cohort study. <i>IJC Heart and Vasculature</i> , 2021, 36, 100853.	0.6	4

#	ARTICLE	IF	CITATIONS
73	Medically Ill hospitalized Patients for COVID-19 THrombosis Extended Prophylaxis with rivaroxaban Therapy: Rationale and Design of the MICHELLE Trial. American Heart Journal, 2021, 242, 115-122.	1.2	18
74	Research Priorities in Atrial Fibrillation Screening. Circulation, 2021, 143, 372-388.	1.6	42
75	Effect of tocilizumab on clinical outcomes at 15 days in patients with severe or critical coronavirus disease 2019: randomised controlled trial. BMJ, The, 2021, 372, n84.	3.0	309
76	Predictors of Atrial Fibrillation Development in Patients With Embolic Stroke of Undetermined Source: An Analysis of the RE-SPECT ESUS Trial. Circulation, 2021, 144, 1738-1746.	1.6	31
77	Telemedicine for the treatment of foot ulcers in people with diabetes. The Cochrane Library, 2021, .	1.5	0
78	Age-adjusted D-dimer cutoffs to guide anticoagulation in COVID-19 – Authors' reply. Lancet, The, 2021, 398, 1304.	6.3	0
79	Ultrasound guidance for arterial (other than femoral) catheterisation in adults. The Cochrane Library, 2021, 2021, CD013585.	1.5	6
80	The multiplication of loaves and fishes approach: a critic to double anti-thrombotics or to double number of ischaemic events?. European Heart Journal - Cardiovascular Pharmacotherapy, 2021, 7, e29-e30.	1.4	0
81	Daprodustat for the Treatment of Anemia in Patients Not Undergoing Dialysis. New England Journal of Medicine, 2021, 385, 2313-2324.	13.9	108
82	Disease Modifying Therapies for Transthyretin Amyloid Cardiomyopathy. , 2021, 1, 144-146.		0
83	The role of triple antithrombotic therapy in patients with atrial fibrillation undergoing percutaneous coronary intervention. Progress in Cardiovascular Diseases, 2021, 69, 11-17.	1.6	1
84	Efficacy and Safety of Antithrombotic Therapy in Patients With Atrial Fibrillation, Recent Acute Coronary Syndrome, or Percutaneous Coronary Intervention and a History of Heart Failure: Insights From the AUGUSTUS Trial. Journal of the American Heart Association, 2021, 10, e023143.	1.6	0
85	Chest Pain Network with Support of Telemedicine: Impact on Reperfusion Therapy and Clinical Outcomes After 8 Years of Experience. Telemedicine Reports, 2021, 2, 284-292.	0.5	0
86	Levosimendan in patients with reduced left ventricular function undergoing isolated coronary or valve surgery. Journal of Thoracic and Cardiovascular Surgery, 2020, 159, 2302-2309.e6.	0.4	40
87	A systematic review of randomized trials comparing double versus triple antithrombotic therapy in patients with atrial fibrillation undergoing percutaneous coronary intervention. Catheterization and Cardiovascular Interventions, 2020, 96, E102-E109.	0.7	10
88	Effects of apixaban compared with warfarin as gain in event-free time – a novel assessment of the results of the ARISTOTLE trial. European Journal of Preventive Cardiology, 2020, 27, 1311-1319.	0.8	4
89	Gastrointestinal bleeding in patients with atrial fibrillation treated with Apixaban or warfarin: Insights from the Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation (ARISTOTLE) trial. American Heart Journal, 2020, 221, 1-8.	1.2	19
90	Stent Thrombosis in Patients With Atrial Fibrillation Undergoing Coronary Stenting in the AUGUSTUS Trial. Circulation, 2020, 141, 781-783.	1.6	80

#	ARTICLE	IF	CITATIONS
91	Regional variation in clinical characteristics and outcomes in patients with atrial fibrillation: Findings from the ARISTOTLE trial. <i>International Journal of Cardiology</i> , 2020, 302, 53-58.	0.8	5
92	Microvascular and Cardiovascular Outcomes According to Renal Function in Patients Treated With Once-Weekly Exenatide: Insights From the EXSCEL Trial. <i>Diabetes Care</i> , 2020, 43, 446-452.	4.3	63
93	Anticoagulation in COVID-19. <i>Journal of the American College of Cardiology</i> , 2020, 76, 1827-1829.	1.2	10
94	Prognostic value of myocardial fibrosis on cardiac magnetic resonance imaging in patients with ischemic cardiomyopathy: A systematic review. <i>American Heart Journal</i> , 2020, 229, 52-60.	1.2	9
95	Angiotensin-converting enzyme 2 (ACE2) levels in relation to risk factors for COVID-19 in two large cohorts of patients with atrial fibrillation. <i>European Heart Journal</i> , 2020, 41, 4037-4046.	1.0	90
96	Consumer-led screening for atrial fibrillation using consumer-facing wearables, devices and apps: A survey of health care professionals by AF-SCREEN international collaboration. <i>European Journal of Internal Medicine</i> , 2020, 82, 97-104.	1.0	38
97	COVID-19 in Brazil: the headlines should be about science. <i>Lancet, The</i> , 2020, 396, 1803.	6.3	4
98	Cause of Death Among Patients With Peripheral Artery Disease. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2020, 13, e006550.	0.9	10
99	Management of Atrial Fibrillation in Older Patients by Morbidity Burden: Insights From Get With The Guidelines—Atrial Fibrillation. <i>Journal of the American Heart Association</i> , 2020, 9, e017024.	1.6	23
100	Rivaroxaban in Patients with Atrial Fibrillation and a Bioprosthetic Mitral Valve. <i>New England Journal of Medicine</i> , 2020, 383, 2117-2126.	13.9	161
101	The atrial Fibrillation real World management registry in the Middle East and Africa: design and rationale. <i>Journal of Cardiovascular Medicine</i> , 2020, 21, 704-710.	0.6	2
102	Outcomes following revascularization with radial artery bypass grafts: Insights from the PREVENT-IV trial. <i>American Heart Journal</i> , 2020, 228, 91-97.	1.2	6
103	Hydroxychloroquine with or without Azithromycin in Mild-to-Moderate Covid-19. <i>New England Journal of Medicine</i> , 2020, 383, 2041-2052.	13.9	903
104	Randomized Trials Versus Common Sense and Clinical Observation. <i>Journal of the American College of Cardiology</i> , 2020, 76, 580-589.	1.2	50
105	Antithrombotic therapy for patients with atrial fibrillation undergoing percutaneous coronary intervention: balance best with double antithrombotic therapy. <i>European Heart Journal</i> , 2020, 41, 4505-4507.	1.0	3
106	Azithromycin in addition to standard of care versus standard of care alone in the treatment of patients admitted to the hospital with severe COVID-19 in Brazil (COALITION II): a randomised clinical trial. <i>Lancet, The</i> , 2020, 396, 959-967.	6.3	278
107	Initial Invasive Versus Conservative Management of Stable Ischemic Heart Disease in Patients With a History of Heart Failure or Left Ventricular Dysfunction. <i>Circulation</i> , 2020, 142, 1725-1735.	1.6	77
108	Evaluation of the Age, Biomarkers, and Clinical History—Bleeding Risk Score in Patients With Atrial Fibrillation With Combined Aspirin and Anticoagulation Therapy Enrolled in the ARISTOTLE and RE-LY Trials. <i>JAMA Network Open</i> , 2020, 3, e2015943.	2.8	5

#	ARTICLE	IF	CITATIONS
109	Screening of Multiple Biomarkers Associated With Ischemic Stroke in Atrial Fibrillation. <i>Journal of the American Heart Association</i> , 2020, 9, e018984.	1.6	37
110	Cost-Effectiveness of Alirocumab in Patients With Acute Coronary Syndromes. <i>Journal of the American College of Cardiology</i> , 2020, 75, 2297-2308.	1.2	48
111	Continuing versus suspending angiotensin-converting enzyme inhibitors and angiotensin receptor blockers: Impact on adverse outcomes in hospitalized patients with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)–The BRACE CORONA Trial. <i>American Heart Journal</i> , 2020, 226, 49-59.	1.2	118
112	Is Hypertension a Real Risk Factor for Poor Prognosis in the COVID-19 Pandemic?. <i>Current Hypertension Reports</i> , 2020, 22, 43.	1.5	37
113	Ultrasound guidance for arterial (other than femoral) catheterisation in adults. <i>The Cochrane Library</i> , 2020, , .	1.5	3
114	Serial measurement of interleukin-6 and risk of mortality in anticoagulated patients with atrial fibrillation: Insights from ARISTOTLE and RE-LY trials. <i>Journal of Thrombosis and Haemostasis</i> , 2020, 18, 2287-2295.	1.9	14
115	Clinical and Pharmacological Effects of Apixaban Dose Adjustment in the ARISTOTLE Trial. <i>Journal of the American College of Cardiology</i> , 2020, 75, 1145-1155.	1.2	28
116	Risk/Benefit Tradeoff of Antithrombotic Therapy in Patients With Atrial Fibrillation Early and Late After an Acute Coronary Syndrome or Percutaneous Coronary Intervention. <i>Circulation</i> , 2020, 141, 1618-1627.	1.6	84
117	Apixaban Versus Warfarin in Patients With Atrial Fibrillation and Advanced Chronic Kidney Disease. <i>Circulation</i> , 2020, 141, 1384-1392.	1.6	87
118	Post-Discharge Bleeding and Mortality Following Acute Coronary Syndromes With or Without PCI. <i>Journal of the American College of Cardiology</i> , 2020, 76, 162-171.	1.2	50
119	Rationale and design for the study Apixaban versus Clopidogrel on a background of aspirin in patient undergoing InfraPopliteal angioplasty for critical limb ischemia: AGRIPPA trial. <i>American Heart Journal</i> , 2020, 227, 100-106.	1.2	19
120	A review of global health technology assessments of non-VKA oral anticoagulants in non-valvular atrial fibrillation. <i>International Journal of Cardiology</i> , 2020, 319, 85-93.	0.8	4
121	Evidence-Based Practical Guidance for the Antithrombotic Management in Patients With Coronavirus Disease (COVID-19) in 2020. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 2020, 26, 107602962093635.	0.7	25
122	Optimal Antithrombotic Regimens for Patients With Atrial Fibrillation Undergoing Percutaneous Coronary Intervention. <i>JAMA Cardiology</i> , 2020, 5, 582.	3.0	71
123	Dual-pathway inhibition for secondary and tertiary antithrombotic prevention in cardiovascular disease. <i>Nature Reviews Cardiology</i> , 2020, 17, 242-257.	6.1	87
124	Chagas disease: still a neglected emergency?. <i>Lancet</i> , The, 2020, 395, 1113-1114.	6.3	5
125	Methods for safety and endpoint ascertainment: identification of adverse events through scrutiny of negatively adjudicated events. <i>Trials</i> , 2020, 21, 323.	0.7	3
126	Association Between Delays in Mechanical Ventilation Initiation and Mortality in Patients With Refractory Cardiogenic Shock. <i>JAMA Cardiology</i> , 2020, 5, 965.	3.0	18

#	ARTICLE	IF	CITATIONS
127	Levels of evidence supporting drug, device, and other recommendations in the American Heart Association/American College of Cardiology guidelines. <i>American Heart Journal</i> , 2020, 226, 4-12.	1.2	6
128	New Approaches to Conducting Randomized Controlled Trials. <i>Journal of the American College of Cardiology</i> , 2020, 75, 556-559.	1.2	17
129	Pandemônio Durante a Pandemia: Qual o Papel dos Profissionais da Saúde e a Ciência?. <i>Arquivos Brasileiros De Cardiologia</i> , 2020, 114, 753-754.	0.3	8
130	Avaliação do Seguimento de 1 Ano dos Pacientes Incluídos no Registro da Prática Clínica em Pacientes de Alto Risco Cardiovascular (REACT). <i>Arquivos Brasileiros De Cardiologia</i> , 2020, 116, 108-116.	0.3	7
131	Central Adjudication Identified Additional and Prognostically Important Myocardial Infarctions in Patients Undergoing Percutaneous Coronary Intervention. <i>Circulation: Cardiovascular Interventions</i> , 2019, 12, e007342.	1.4	10
132	Prevalence of atrial fibrillation and stroke risk assessment based on telemedicine screening tools in a primary healthcare setting. <i>European Journal of Internal Medicine</i> , 2019, 67, 36-41.	1.0	19
133	Clinical consequences of bleeding among individuals with a recent acute coronary syndrome: Insights from the APPRAISE-2 trial. <i>American Heart Journal</i> , 2019, 215, 106-113.	1.2	7
134	Relation of Postdischarge Care Fragmentation and Outcomes in Transcatheter Aortic Valve Implantation from the STS/ACC TVT Registry. <i>American Journal of Cardiology</i> , 2019, 124, 912-919.	0.7	9
135	Oral anticoagulation for subclinical atrial tachyarrhythmias detected by implantable cardiac devices: an international survey of the AF-SCREEN Group. <i>International Journal of Cardiology</i> , 2019, 296, 65-70.	0.8	14
136	Management of Antithrombotic Therapy in Atrial Fibrillation Patients Undergoing PPCI. <i>Journal of the American College of Cardiology</i> , 2019, 74, 83-99.	1.2	126
137	Effects of alirocumab on cardiovascular and metabolic outcomes after acute coronary syndrome in patients with or without diabetes: a prespecified analysis of the ODYSSEY OUTCOMES randomised controlled trial. <i>Lancet Diabetes and Endocrinology</i> , 2019, 7, 618-628.	5.5	207
138	High-quality evidence to inform clinical practice. <i>Lancet</i> , 2019, 394, 633-634.	6.3	10
139	Characteristics and Outcomes of Atrial Fibrillation in Patients With Thyroid Disease (from the Tj ETQq1 1 0.784314 rgrBT /Overlock 10	0.7	18
140	New antihyperglycemic medications with cardiovascular protection for patients with diabetes: What do surgeons need to know?. <i>Journal of Thoracic and Cardiovascular Surgery</i> , 2019, 158, 1113-1117.	0.4	2
141	Impact of Polypharmacy and P-Glycoprotein- and CYP3A4-Modulating Drugs on Safety and Efficacy of Oral Anticoagulation Therapy in Patients with Atrial Fibrillation. <i>Cardiovascular Drugs and Therapy</i> , 2019, 33, 615-623.	1.3	41
142	Antithrombotic Therapy in Patients With Atrial Fibrillation and Acute Coronary Syndrome Treated Medically or With Percutaneous Coronary Intervention or Undergoing Elective Percutaneous Coronary Intervention. <i>Circulation</i> , 2019, 140, 1921-1932.	1.6	57
143	Hospitalization Among Patients With Atrial Fibrillation and a Recent Acute Coronary Syndrome or Percutaneous Coronary Intervention Treated With Apixaban or Aspirin. <i>Circulation</i> , 2019, 140, 1960-1963.	1.6	7
144	International variation in characteristics and clinical outcomes of patients with type 2 diabetes and heart failure: Insights from TECOS. <i>American Heart Journal</i> , 2019, 218, 57-65.	1.2	4

#	ARTICLE	IF	CITATIONS
145	Claims-based cardiovascular outcome identification for clinical research: Results from 7 large randomized cardiovascular clinical trials. <i>American Heart Journal</i> , 2019, 218, 110-122.	1.2	7
146	Effect of Once-Weekly Exenatide in Patients With Type 2 Diabetes Mellitus With and Without Heart Failure and Heart Failure-Related Outcomes. <i>Circulation</i> , 2019, 140, 1613-1622.	1.6	58
147	Zika and Chikungunya Virus and Risk for Venous Thromboembolism. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 2019, 25, 107602961882118.	0.7	51
148	Direct Oral Anticoagulants and Cancer-Associated Thrombosis Management. Where Do We Stand in 2019?. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 2019, 25, 107602961985643.	0.7	3
149	Navigating the treacherous waters of antithrombotic therapies in patients with atrial fibrillation and coronary artery disease: Lessons from AUGUSTUS. <i>European Journal of Internal Medicine</i> , 2019, 65, 4-5.	1.0	4
150	Ticagrelor in patients with heart failure after acute coronary syndromes—Insights from the PLATelet inhibition and patient Outcomes (PLATO) trial. <i>American Heart Journal</i> , 2019, 213, 57-65.	1.2	7
151	Antithrombotic treatment gap among patients with atrial fibrillation and type 2 diabetes. <i>International Journal of Cardiology</i> , 2019, 289, 58-62.	0.8	2
152	Effect of a Quality Improvement Intervention on Adherence to Therapies for Patients With Acute Ischemic Stroke and Transient Ischemic Attack. <i>JAMA Neurology</i> , 2019, 76, 932.	4.5	23
153	International normalized ratio control and subsequent clinical outcomes in patients with atrial fibrillation using warfarin. <i>Journal of Thrombosis and Thrombolysis</i> , 2019, 48, 27-34.	1.0	11
154	Atrial fibrillation: what do we know about screening and what do we not know about treatment?. <i>Heart</i> , 2019, 105, 817-819.	1.2	2
155	Antithrombotic Therapy after Acute Coronary Syndrome or PCI in Atrial Fibrillation. <i>New England Journal of Medicine</i> , 2019, 380, 1509-1524.	13.9	833
156	Efficacy and safety of apixaban vs warfarin in patients with atrial fibrillation and prior bioprosthetic valve replacement or valve repair: Insights from the ARISTOTLE trial. <i>Clinical Cardiology</i> , 2019, 42, 568-571.	0.7	80
157	Levels of Evidence Supporting American College of Cardiology/American Heart Association and European Society of Cardiology Guidelines, 2008-2018. <i>JAMA - Journal of the American Medical Association</i> , 2019, 321, 1069.	3.8	144
158	Interacting medication use and the treatment effects of apixaban versus warfarin: results from the ARISTOTLE Trial. <i>Journal of Thrombosis and Thrombolysis</i> , 2019, 47, 345-352.	1.0	13
159	Baseline Characteristics and Risk Profiles of Participants in the ISCHEMIA Randomized Clinical Trial. <i>JAMA Cardiology</i> , 2019, 4, 273.	3.0	100
160	Efficacy and Safety of Apixaban Versus Warfarin in Patients With Atrial Fibrillation and Extremes in Body Weight. <i>Circulation</i> , 2019, 139, 2292-2300.	1.6	78
161	Peripheral blood metabolite profiles associated with new onset atrial fibrillation. <i>American Heart Journal</i> , 2019, 211, 54-59.	1.2	9
162	Antithrombotic therapy after acute coronary syndrome and/or percutaneous coronary intervention in atrial fibrillation: finding the sweet spot. <i>European Heart Journal</i> , 2019, 40, 3768-3770.	1.0	11

#	ARTICLE	IF	CITATIONS
163	Effect of apixaban compared with warfarin on coagulation markers in atrial fibrillation. <i>Heart</i> , 2019, 105, 235-242.	1.2	19
164	Comparison of Outcomes and Frequency of Graft Failure With Use of Free Versus In Situ Internal Mammmary Artery Bypass Conduits (from the PREVENT IV Trial). <i>American Journal of Cardiology</i> , 2019, 123, 571-575.	0.7	8
165	Efficacy and safety of reduced-dose non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation: a meta-analysis of randomized controlled trials. <i>European Heart Journal</i> , 2019, 40, 1492-1500.	1.0	45
166	Frequency, Regional Variation, and Predictors of Undetermined Cause of Death in Cardiometabolic Clinical Trials: A Pooled Analysis of 9259 Deaths in 9 Trials. <i>Circulation</i> , 2019, 139, 863-873.	1.6	18
167	Characterization of cardiovascular clinical events and impact of event adjudication on the treatment effect of darapladib versus placebo in patients with stable coronary heart disease: Insights from the STABILITY trial. <i>American Heart Journal</i> , 2019, 208, 65-73.	1.2	14
168	Outcomes of apixaban versus warfarin in patients with atrial fibrillation and multi-morbidity: Insights from the ARISTOTLE trial. <i>American Heart Journal</i> , 2019, 208, 123-131.	1.2	54
169	Idarucizumab for Dabigatran Reversal in the Management of Patients With Gastrointestinal Bleeding. <i>Circulation</i> , 2019, 139, 748-756.	1.6	36
170	Rationale and design for a cluster randomized quality-improvement trial to increase the uptake of evidence-based therapies for patients at high cardiovascular risk: The BRIDGE-Cardiovascular Prevention trial. <i>American Heart Journal</i> , 2019, 207, 40-48.	1.2	3
171	Usefulness of Antithrombotic Therapy in Patients With Atrial Fibrillation and Acute Myocardial Infarction. <i>American Journal of Cardiology</i> , 2019, 123, 12-18.	0.7	17
172	Meta-Analysis of Effects of Digoxin on Survival in Patients with Atrial Fibrillation or Heart Failure: An Update. <i>American Journal of Cardiology</i> , 2019, 123, 69-74.	0.7	50
173	An international cluster-randomized quality improvement trial to increase the adherence to evidence-based therapies for acute ischemic stroke and transient ischemic attack patients: Rationale and design of the BRIDGE STROKE Trial. <i>American Heart Journal</i> , 2019, 207, 49-57.	1.2	10
174	Development and validation of a questionnaire to assess the knowledge of mechanical ventilation in urgent care among students in their last-year medical course in Brazil. <i>Clinics</i> , 2019, 74, e663.	0.6	2
175	Linking stroke-induced heart injury and neurogenic atrial fibrillation: a hypothesis to be proven. <i>Journal of Electrocardiology</i> , 2018, 51, 430-432.	0.4	22
176	Digoxin and Mortality in Patients With Atrial Fibrillation. <i>Journal of the American College of Cardiology</i> , 2018, 71, 1063-1074.	1.2	147
177	Stroke prevention in atrial fibrillation: re-defining "real-world data" within the broader data universe. <i>European Heart Journal</i> , 2018, 39, 2932-2941.	1.0	22
178	Disentangling the risk of atrial fibrillation detected after ischemic stroke (AFDAS): A real challenge in clinical practice. <i>International Journal of Cardiology</i> , 2018, 261, 99-100.	0.8	3
179	Dual antiplatelet therapy for perioperative myocardial infarction following CABG surgery. <i>American Heart Journal</i> , 2018, 199, 150-155.	1.2	2
180	Outcomes in anticoagulated patients with atrial fibrillation and with mitral or aortic valve disease. <i>Heart</i> , 2018, 104, 1292-1299.	1.2	14

#	ARTICLE	IF	CITATIONS
181	Oral anticoagulation: a step toward solving the puzzle of dementia related to atrial fibrillation?. <i>European Heart Journal</i> , 2018, 39, 461-463.	1.0	4
182	An open-Label, 2 × 2 factorial, randomized controlled trial to evaluate the safety of apixaban vs. vitamin K antagonist and aspirin vs. placebo in patients with atrial fibrillation and acute coronary syndrome and/or percutaneous coronary intervention: Rationale and design of the AUGUSTUS trial. <i>American Heart Journal</i> , 2018, 200, 17-23.	1.2	69
183	Highlights from the Tenth International Symposium of Thrombosis and Anticoagulation (ISTA X), September 22 and 23, 2017, Salvador, Bahia, Brazil. <i>Journal of Thrombosis and Thrombolysis</i> , 2018, 45, 578-587.	1.0	0
184	Effect of Loading Dose of Atorvastatin Prior to Planned Percutaneous Coronary Intervention on Major Adverse Cardiovascular Events in Acute Coronary Syndrome. <i>JAMA - Journal of the American Medical Association</i> , 2018, 319, 1331.	3.8	100
185	Ticagrelor vs Clopidogrel After Fibrinolytic Therapy in Patients With ST-Elevation Myocardial Infarction. <i>JAMA Cardiology</i> , 2018, 3, 391.	3.0	65
186	Apixaban following acute coronary syndromes in patients with prior stroke: Insights from the APPRAISE-2 trial. <i>American Heart Journal</i> , 2018, 197, 1-8.	1.2	6
187	Percutaneous coronary intervention and antiplatelet therapy in patients with atrial fibrillation receiving apixaban or warfarin: Insights from the ARISTOTLE trial. <i>American Heart Journal</i> , 2018, 197, 133-141.	1.2	17
188	Clinical Outcomes and History of Fall in Patients with Atrial Fibrillation Treated with Oral Anticoagulation: Insights From the ARISTOTLE Trial. <i>American Journal of Medicine</i> , 2018, 131, 269-275.e2.	0.6	87
189	Pathophysiology and Risk of Atrial Fibrillation Detected after Ischemic Stroke (PARADISE): A Translational, Integrated, and Transdisciplinary Approach. <i>Journal of Stroke and Cerebrovascular Diseases</i> , 2018, 27, 606-619.	0.7	12
190	Obesity paradox on outcome in atrial fibrillation maintained even considering the prognostic influence of biomarkers: insights from the ARISTOTLE trial. <i>Open Heart</i> , 2018, 5, e000908.	0.9	12
191	Days Alive and Out of Hospital: Exploring a Patient-Centered, Pragmatic Outcome in a Clinical Trial of Patients With Acute Coronary Syndromes. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2018, 11, e004755.	0.9	51
192	Cardiovascular and Limb Outcomes in Patients With Diabetes and Peripheral Artery Disease. <i>Journal of the American College of Cardiology</i> , 2018, 72, 3274-3284.	1.2	64
193	Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial. <i>Lancet</i> , 2018, 392, 1519-1529.	6.3	1,179
194	The First Brazilian Registry of Hypertension. <i>American Heart Journal</i> , 2018, 205, 154-157.	1.2	14
195	Effectiveness and Safety of Anticoagulants in Adults with Non-valvular Atrial Fibrillation and Concomitant Coronary/Peripheral Artery Disease. <i>American Journal of Medicine</i> , 2018, 131, 1075-1085.e4.	0.6	15
196	Periprocedural Outcomes of Direct Oral Anticoagulants Versus Warfarin in Nonvalvular Atrial Fibrillation. <i>Circulation</i> , 2018, 138, 1402-1411.	1.6	26
197	Usefulness and Cost-Effectiveness of Universal Echocardiographic Contrast to Detect Left Ventricular Thrombus in Patients with Heart Failure and Reduced Ejection Fraction. <i>American Journal of Cardiology</i> , 2018, 122, 121-128.	0.7	6
198	Reply. <i>Journal of the American College of Cardiology</i> , 2018, 72, 125-126.	1.2	0

#	ARTICLE	IF	CITATIONS
199	Implementation of a Regional Network for STâ€Segmentâ€Elevation Myocardial Infarction (STEMI) Care and 30â€Day Mortality in a Lowâ€to Middleâ€Income City in Brazil: Findings From Salvador's STEMI Registry (RESISST). <i>Journal of the American Heart Association</i> , 2018, 7, .	1.6	26
200	Asymmetric and Symmetric Dimethylarginine Predict Outcomes in Patients With Atrial Fibrillation. <i>Journal of the American College of Cardiology</i> , 2018, 72, 721-733.	1.2	31
201	Ticagrelor versus clopidogrel in patients with symptomatic peripheral artery disease and prior coronary artery disease: Insights from the EUCLID trial. <i>Vascular Medicine</i> , 2018, 23, 523-530.	0.8	29
202	Incidence, timing, and type of first and recurrent ischemic events in patients with and without peripheral artery disease after an acute coronary syndrome. <i>American Heart Journal</i> , 2018, 201, 25-32.	1.2	9
203	Epicardial adipose tissue and carotid artery disease. <i>Medicine (United States)</i> , 2018, 97, e0273.	0.4	2
204	The Use of Oral Beta-Blockers and Clinical Outcomes in Patients with Non-ST-Segment Elevation Acute Coronary Syndromes: a Long-Term Follow-Up Study. <i>Cardiovascular Drugs and Therapy</i> , 2018, 32, 435-442.	1.3	7
205	The high cost of critical care unit over-utilization for patients with NSTEMI ACS. <i>American Heart Journal</i> , 2018, 202, 84-88.	1.2	19
206	Definitions of peri-procedural myocardial infarction and the association with one-year mortality: Insights from CHAMION trials. <i>International Journal of Cardiology</i> , 2018, 270, 96-101.	0.8	10
207	Coronary Artery Fistula Causing Acute Myocardial Infarction and Right Ventricle Thrombus. <i>Cureus</i> , 2018, 10, e2314.	0.2	1
208	Paradoxical Embolism in a Patient with Aortic Valve Endocarditis: A Case Report. <i>Cureus</i> , 2018, 10, e2301.	0.2	0
209	International Variation in Outcomes Among People with Cardiovascular Disease or Cardiovascular Risk Factors and Impaired Glucose Tolerance: Insights from the NAVIGATOR Trial. <i>Journal of the American Heart Association</i> , 2017, 6, .	1.6	4
210	Efficacy and Safety of Apixaban Compared With Warfarin in Patients With Atrial Fibrillation and Peripheral Artery Disease: Insights From the ARISTOTLE Trial. <i>Journal of the American Heart Association</i> , 2017, 6, .	1.6	34
211	Noncardiovascular deaths are more common than cardiovascular deaths in patients with cardiovascular disease or cardiovascular risk factors and impaired glucose tolerance: Insights from the Nateglinide and Valsartan in Impaired Glucose Tolerance Outcomes Research (NAVIGATOR) trial. <i>American Heart Journal</i> . 2017, 186, 73-82.	1.2	16
212	Anemia is associated with bleeding and mortality, but not stroke, in patients with atrial fibrillation: Insights from the Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation (ARISTOTLE) trial. <i>American Heart Journal</i> , 2017, 185, 140-149.	1.2	54
213	Balancing the risk of spontaneous ischemic and major bleeding events in acute coronary syndromes. <i>American Heart Journal</i> , 2017, 186, 91-99.	1.2	36
214	Angiotensin Receptor Blockade Improves Cardiac Surgical Outcomes in Patients With Metabolic Syndrome. <i>Annals of Thoracic Surgery</i> , 2017, 104, 98-105.	0.7	7
215	Non-major bleeding with apixaban versus warfarin in patients with atrial fibrillation. <i>Heart</i> , 2017, 103, 623-628.	1.2	54
216	Obesity, Diabetes, and Acute Coronary Syndrome: Differences Between Asians and Whites. <i>American Journal of Medicine</i> , 2017, 130, 1170-1176.	0.6	8

#	ARTICLE	IF	CITATIONS
217	Rationale and design of the Apixaban for the Reduction of Thrombo-Embolism in Patients With Device-Detected Sub-Clinical Atrial Fibrillation (ARTESiA) trial. <i>American Heart Journal</i> , 2017, 189, 137-145.	1.2	258
218	Effect of Apixaban on All-Cause Death in Patients with Atrial Fibrillation: a Meta-Analysis Based on Imputed Placebo Effect. <i>Cardiovascular Drugs and Therapy</i> , 2017, 31, 295-301.	1.3	3
219	Reporting Clinical End Points and Safety Events in an Acute Coronary Syndrome Trial: Results With Integrated Collection. <i>Journal of the American Heart Association</i> , 2017, 6, .	1.6	8
220	Cardiovascular adverse events in the drug development program of bupropion for smoking cessation: A systematic retrospective adjudication effort. <i>Clinical Cardiology</i> , 2017, 40, 899-906.	0.7	3
221	Economic Analysis of Apixaban Therapy for Patients With Atrial Fibrillation From a US Perspective. <i>JAMA Cardiology</i> , 2017, 2, 525.	3.0	18
222	Intracranial hemorrhage in patients with atrial fibrillation receiving anticoagulation therapy. <i>Blood</i> , 2017, 129, 2980-2987.	0.6	85
223	Differential occurrence, profile, and impact of first recurrent cardiovascular events after an acute coronary syndrome. <i>American Heart Journal</i> , 2017, 187, 194-203.	1.2	26
224	Association between CK-MB Area Under the Curve and Tranexamic Acid Utilization in Patients Undergoing Coronary Artery Bypass Surgery. <i>Journal of Thrombosis and Thrombolysis</i> , 2017, 43, 446-453.	1.0	5
225	Echocardiographic Risk Factors for Stroke and Outcomes in Patients With Atrial Fibrillation Anticoagulated With Apixaban or Warfarin. <i>Stroke</i> , 2017, 48, 3266-3273.	1.0	20
226	Causes of Death in a Contemporary Cohort of Patients With Type 2 Diabetes and Atherosclerotic Cardiovascular Disease: Insights From the TECOS Trial. <i>Diabetes Care</i> , 2017, 40, 1763-1770.	4.3	60
227	Highlights from the Ninth International Symposium of Thrombosis and Anticoagulation (ISTA IX), October 15, 2016, Salvador, Bahia, Brazil. <i>Journal of Thrombosis and Thrombolysis</i> , 2017, 44, 544-555.	1.0	0
228	Glycemic control in patients undergoing coronary artery bypass graft surgery: Clinical features, predictors, and outcomes. <i>Journal of Critical Care</i> , 2017, 42, 328-333.	1.0	10
229	Selection of Stent Type in Patients With Atrial Fibrillation Presenting With Acute Myocardial Infarction: An Analysis From the ACTION (Acute Coronary Treatment and Intervention Outcomes) Trial. <i>Journal of the American Heart Association</i> , 2017, 6, .	1.0	10
230	Regional differences in presentation and antithrombotic treatment of patients with atrial fibrillation: Baseline characteristics from a clustered randomized trial to IMProve treatment with AntiCoagulanTs in patients with atrial fibrillation (IMPACT-AF). <i>American Heart Journal</i> , 2017, 192, 38-47.	1.2	5
231	Efficacy and Safety of Apixaban Versus Warfarin in Patients with Atrial Fibrillation and a History of Cancer: Insights from the ARISTOTLE Trial. <i>American Journal of Medicine</i> , 2017, 130, 1440-1448.e1.	0.6	120
232	Repeated Measurements of Cardiac Biomarkers in Atrial Fibrillation and Validation of the ABC Stroke Score Over Time. <i>Journal of the American Heart Association</i> , 2017, 6, .	1.6	20
233	Anticoagulation therapy and clinical outcomes in patients with recently diagnosed atrial fibrillation: Insights from the ARISTOTLE trial. <i>International Journal of Cardiology</i> , 2017, 227, 443-449.	0.8	3
234	Nonsteroidal Anti-Inflammatory Drugs and Clinical Outcomes in Patients Undergoing Coronary Artery Bypass Surgery. <i>American Journal of Medicine</i> , 2017, 130, 462-468.	0.6	19

#	ARTICLE	IF	CITATIONS
235	A multifaceted intervention to improve treatment with oral anticoagulants in atrial fibrillation (IMPACT-AF): an international, cluster-randomised trial. <i>Lancet, The</i> , 2017, 390, 1737-1746.	6.3	154
236	Evaluation of self-perception of mechanical ventilation knowledge among Brazilian final-year medical students, residents and emergency physicians. <i>Clinics</i> , 2017, 72, 65-70.	0.6	18
237	Mechanical Ventilation and Clinical Outcomes in Patients with Acute Myocardial Infarction: A Retrospective Observational Study. <i>PLoS ONE</i> , 2016, 11, e0151302.	1.1	7
238	Predicting Outcomes Over Time in Patients With Heart Failure, Left Ventricular Systolic Dysfunction, or Both Following Acute Myocardial Infarction. <i>Journal of the American Heart Association</i> , 2016, 5, .	1.6	4
239	A clustered randomized trial to IMProve treatment with AntiCoagulanTs in patients with Atrial Fibrillation (IMPACT-AF): design and rationale. <i>American Heart Journal</i> , 2016, 176, 107-113.	1.2	8
240	The novel biomarker-based ABC (age, biomarkers, clinical history)-bleeding risk score for patients with atrial fibrillation: a derivation and validation study. <i>Lancet, The</i> , 2016, 387, 2302-2311.	6.3	389
241	Association Between Sitagliptin Use and Heart Failure Hospitalization and Related Outcomes in Type 2 Diabetes Mellitus. <i>JAMA Cardiology</i> , 2016, 1, 126.	3.0	196
242	The "obesity paradox"™ in atrial fibrillation: observations from the ARISTOTLE (Apixaban for Reduction in Thrombotic and Other Major Complications in Atrial Fibrillation) Trial. <i>Circulation</i> , 2016, 133, 2869-2878.	1.0	194
243	Trends in Enrollment, Clinical Characteristics, Treatment, and Outcomes According to Age in Non-ST-Segment Elevation Acute Coronary Syndromes Clinical Trials. <i>Circulation</i> , 2016, 133, 1560-1573.	1.6	17
244	First-Ever Stroke and Transient Ischemic Attack Incidence and 30-Day Case-Fatality Rates in a Population-Based Study in Argentina. <i>Stroke</i> , 2016, 47, 1640-1642.	1.0	42
245	North American Thrombosis Forum, AF Action Initiative Consensus Document. <i>American Journal of Medicine</i> , 2016, 129, S1-S29.	0.6	24
246	Impact of glycoprotein IIb/IIIa inhibitors on the efficacy and safety of ticagrelor compared with clopidogrel in patients with acute coronary syndromes: Analysis from the Platelet Inhibition and Patient Outcomes (PLATO) Trial. <i>American Heart Journal</i> , 2016, 177, 1-8.	1.2	23
247	Effect of age on efficacy and safety of vorapaxar in patients with non-ST-segment elevation acute coronary syndrome: Insights from the Thrombin Receptor Antagonist for Clinical Event Reduction in Acute Coronary Syndrome (TRACER) trial. <i>American Heart Journal</i> , 2016, 178, 176-184.	1.2	5
248	A time-series analysis of the relation between unemployment rate and hospital admission for acute myocardial infarction and stroke in Brazil over more than a decade. <i>International Journal of Cardiology</i> , 2016, 224, 33-36.	0.8	10
249	Letter by Hess et al Regarding Article, "How to Manage Occult Atrial Fibrillation Detected on Long-Term Monitoring". <i>Circulation</i> , 2016, 134, e28-9.	1.6	2
250	Dual Antiplatelet Therapy and Outcomes in Patients With Atrial Fibrillation and Acute Coronary Syndromes Managed Medically Without Revascularization: Insights From the TRILOGY ACS Trial. <i>Clinical Cardiology</i> , 2016, 39, 497-506.	0.7	5
251	A Brazilian perspective for the use of bovine heparin in open heart surgery. <i>International Journal of Cardiology</i> , 2016, 223, 611-612.	0.8	8
252	Performance and Validation of a Novel Biomarker-Based Stroke Risk Score for Atrial Fibrillation. <i>Circulation</i> , 2016, 134, 1697-1707.	1.6	76

#	ARTICLE	IF	CITATIONS
253	Use of Direct Oral Anticoagulants in Special Populations. <i>Hematology/Oncology Clinics of North America</i> , 2016, 30, 1053-1071.	0.9	3
254	Effect of Sitagliptin on Kidney Function and Respective Cardiovascular Outcomes in Type 2 Diabetes: Outcomes From TECOS. <i>Diabetes Care</i> , 2016, 39, 2304-2310.	4.3	142
255	Efficacy and Safety of Apixaban Compared With Warfarin in Patients With Atrial Fibrillation in Relation to Renal Function Over Time. <i>JAMA Cardiology</i> , 2016, 1, 451.	3.0	137
256	Guidance for the treatment of deep vein thrombosis and pulmonary embolism. <i>Journal of Thrombosis and Thrombolysis</i> , 2016, 41, 32-67.	1.0	243
257	Triple vs Dual Antithrombotic Therapy in Patients with Atrial Fibrillation and Coronary Artery Disease. <i>American Journal of Medicine</i> , 2016, 129, 592-599.e1.	0.6	49
258	Frequency and Predictors of Internal Mammary Artery Graft Failure and Subsequent Clinical Outcomes. <i>Circulation</i> , 2016, 133, 131-138.	1.6	70
259	Reduction of ischemic events in Improved Reduction of Outcomes: Vytorin Efficacy International Trial: Intensive cholesterol lowering or ezetimibe antithrombotic effects?. <i>American Heart Journal</i> , 2016, 172, 42-44.	1.2	1
260	Spontaneous MI After Non-STEMI-Segment Elevation Acute Coronary Syndrome Managed Without Revascularization. <i>Journal of the American College of Cardiology</i> , 2016, 67, 1289-1297.	1.2	15
261	Biomarkers of inflammation and risk of cardiovascular events in anticoagulated patients with atrial fibrillation. <i>Heart</i> , 2016, 102, 508-517.	1.2	67
262	History of bleeding and outcomes with apixaban versus warfarin in patients with atrial fibrillation in the Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation trial. <i>American Heart Journal</i> , 2016, 175, 175-183.	1.2	16
263	Pooled analysis of adverse event collection from 4 acute coronary syndrome trials. <i>American Heart Journal</i> , 2016, 174, 60-67.	1.2	4
264	The ABC (age, biomarkers, clinical history) stroke risk score: a biomarker-based risk score for predicting stroke in atrial fibrillation. <i>European Heart Journal</i> , 2016, 37, 1582-1590.	1.0	329
265	Rationale and design of the First Brazilian Cardiovascular Registry of Atrial Fibrillation: The RECALL study. <i>American Heart Journal</i> , 2016, 176, 10-16.	1.2	9
266	Renal failure in patients with ST-segment elevation acute myocardial infarction treated with primary percutaneous coronary intervention: Predictors, clinical and angiographic features, and outcomes. <i>American Heart Journal</i> , 2016, 173, 57-66.	1.2	23
267	Effect of the REG1 anticoagulation system versus bivalirudin on outcomes after percutaneous coronary intervention (REGULATE-PCI): a randomised clinical trial. <i>Lancet, The</i> , 2016, 387, 349-356.	6.3	109
268	Chronic obstructive pulmonary disease in patients with atrial fibrillation: Insights from the ARISTOTLE trial. <i>International Journal of Cardiology</i> , 2016, 202, 589-594.	0.8	38
269	Clopidogrel use After Myocardial Revascularization: Prevalence, Predictors, and One-Year Survival Rate. <i>Brazilian Journal of Cardiovascular Surgery</i> , 2016, 31, 106-14.	0.2	3
270	Association of BW with Thromboembolic and Bleeding Outcomes in Phase III Randomized Controlled Trials of Direct Oral Anticoagulants: Systematic Review and Meta-Analysis. <i>Blood</i> , 2016, 128, 88-88.	0.6	0

#	ARTICLE	IF	CITATIONS
271	Clinical outcomes of patients with diabetes and atrial fibrillation treated with apixaban: results from the ARISTOTLE trial. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2015, 1, 86-94.	1.4	59
272	Cumulative Incidence of Death and Rehospitalization Among the Elderly in the First Year after NSTEMI. <i>American Journal of Medicine</i> , 2015, 128, 582-590.	0.6	35
273	Reduced dose tenecteplase and outcomes in elderly ST-segment elevation myocardial infarction patients: Insights from the STRategic Reperfusion Early After Myocardial infarction trial. <i>American Heart Journal</i> , 2015, 169, 890-898.e1.	1.2	26
274	Blood Pressure Control and Risk of Stroke or Systemic Embolism in Patients With Atrial Fibrillation: Results From the Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation (ARISTOTLE) Trial. <i>Journal of the American Heart Association</i> , 2015, 4, .	1.6	68
275	Clinical outcomes in patients with atrial fibrillation according to sex during anticoagulation with apixaban or warfarin: a secondary analysis of a randomized controlled trial. <i>European Heart Journal</i> , 2015, 36, ehv447.	1.0	35
276	Response to Letters Regarding Article, "Saphenous Vein Graft Failure After Coronary Artery Bypass Surgery: Insights From PREVENT IV". <i>Circulation</i> , 2015, 132, e29.	1.6	3
277	Anticoagulant therapy and outcomes in patients with prior or acute heart failure and acute coronary syndromes: Insights from the APixaban for PREvention of Acute ISchemic Events 2 trial. <i>American Heart Journal</i> , 2015, 169, 531-538.	1.2	9
278	The periprocedural management of novel oral anticoagulants in patients with nonvalvular atrial fibrillation: Rationale and a summary of the available evidence from phase 3 clinical trials. <i>American Heart Journal</i> , 2015, 169, 315-322.	1.2	9
279	Comparison of Cardiac Troponins I and T Measured with High-Sensitivity Methods for Evaluation of Prognosis in Atrial Fibrillation: An ARISTOTLE Substudy. <i>Clinical Chemistry</i> , 2015, 61, 368-378.	1.5	37
280	Characterising and predicting bleeding in high-risk patients with an acute coronary syndrome. <i>Heart</i> , 2015, 101, 1475-1484.	1.2	13
281	Response to Letter Regarding Article, "Surgical Revascularization Is Associated With Maximal Survival in Patients With Ischemic Mitral Regurgitation: A 20-year Experience". <i>Circulation</i> , 2015, 131, e378-9.	1.6	1
282	Apixaban in Comparison With Warfarin in Patients With Atrial Fibrillation and Valvular Heart Disease. <i>Circulation</i> , 2015, 132, 624-632.	1.6	203
283	Integrating Electronic Health Records in the Delivery of Optimized Anticoagulation Therapy. <i>Annals of Pharmacotherapy</i> , 2015, 49, 125-126.	0.9	0
284	Apixaban Plus Mono Versus Dual Antiplatelet Therapy in Acute Coronary Syndromes. <i>Journal of the American College of Cardiology</i> , 2015, 66, 777-787.	1.2	39
285	The Preservation and Handling of Vein Grafts in Current Surgical Practice. <i>JAMA Surgery</i> , 2015, 150, 681.	2.2	12
286	Clinical events after transitioning from apixaban versus warfarin to warfarin at the end of the Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation (ARISTOTLE) trial. <i>American Heart Journal</i> , 2015, 169, 25-30.	1.2	61
287	Long-term clinical and angiographic outcomes in patients with diabetes undergoing coronary artery bypass graft surgery: Results from the PROject of Ex-vivo Vein graft ENGINEERING via Transfection IV Trial. <i>American Heart Journal</i> , 2015, 169, 175-184.	1.2	23
288	Clinical outcomes and management associated with major bleeding in patients with atrial fibrillation treated with apixaban or warfarin: insights from the ARISTOTLE trial. <i>European Heart Journal</i> , 2015, 36, 1264-1272.	1.0	144

#	ARTICLE	IF	CITATIONS
289	Venous Thromboembolism and Cardiovascular Risk: Results from the NAVIGATOR Trial. American Journal of Medicine, 2015, 128, 297-302.	0.6	9
290	Abstract 17277: Apixaban Use in Patients With Atrial Fibrillation With Bioprosthetic Valves: Insights From ARISTOTLE. Circulation, 2015, 132, .	1.6	12
291	Isolated Double Orifice Mitral Valve - a Rare Finding in an Elderly Man. Arquivos Brasileiros De Cardiologia, 2015, 104, e53-4.	0.3	0
292	Abstract 17205: Polypharmacy and the Impact of Apixaban on Clinical Events in Patients With Atrial Fibrillation: Insights From the ARISTOTLE Trial. Circulation, 2015, 132, .	1.6	0
293	Abstract 12404: Efficacy and Safety of Apixaban Compared With Warfarin in Patients With Atrial Fibrillation and Normal Renal Function over Time: Insights From the ARISTOTLE Trial. Circulation, 2015, 132, .	1.6	0
294	Abstract 17236: Intracranial Hemorrhage in Patients With Atrial Fibrillation in the ARISTOTLE Trial: Clinical Characteristics and Associated Outcomes. Circulation, 2015, 132, .	1.6	0
295	Efficacy and safety of apixaban compared with warfarin according to age for stroke prevention in atrial fibrillation: observations from the ARISTOTLE trial. European Heart Journal, 2014, 35, 1864-1872.	1.0	303
296	Atrial fibrillation, valvular heart disease, and use of target-specific oral anticoagulants for stroke prevention. European Heart Journal, 2014, 35, 3323-3325.	1.0	7
297	Incidence and predictors of appropriate therapies delivered by the implantable cardioverter defibrillator in patients with ischemic cardiomyopathy: A systematic review. International Journal of Cardiology, 2014, 177, 990-994.	0.8	14
298	Vein Graft Preservation Solutions, Patency, and Outcomes After Coronary Artery Bypass Graft Surgery. JAMA Surgery, 2014, 149, 798.	2.2	74
299	Prevalence, characteristics, and predictors of early termination of cardiovascular clinical trials due to low recruitment: Insights from the ClinicalTrials.gov registry. American Heart Journal, 2014, 168, 213-219.e1.	1.2	73
300	Warfarin use and long-term outcomes in patients with acute myocardial infarction and atrial fibrillation. Journal of Thrombosis and Thrombolysis, 2014, 37, 331-337.	1.0	4
301	Major Bleeding in Patients With Atrial Fibrillation Receiving Apixaban or Warfarin. Journal of the American College of Cardiology, 2014, 63, 2141-2147.	1.2	308
302	High-Sensitivity Troponin T and Risk Stratification in Patients With Atrial Fibrillation During Treatment With Apixaban or Warfarin. Journal of the American College of Cardiology, 2014, 63, 52-61.	1.2	133
303	Efficacy and Safety of Apixaban in Patients After Cardioversion for Atrial Fibrillation. Journal of the American College of Cardiology, 2014, 63, 1082-1087.	1.2	228
304	Growth Differentiation Factor 15, a Marker of Oxidative Stress and Inflammation, for Risk Assessment in Patients With Atrial Fibrillation. Circulation, 2014, 130, 1847-1858.	1.6	243
305	Reply. Annals of Thoracic Surgery, 2014, 98, 1890.	0.7	0
306	Use of antiarrhythmic drug therapy and clinical outcomes in older patients with concomitant atrial fibrillation and coronary artery disease. Europace, 2014, 16, 1284-1290.	0.7	9

#	ARTICLE	IF	CITATIONS
307	Chronic obstructive pulmonary disease and cardiovascular risk: Insights from the NAVIGATOR trial. <i>International Journal of Cardiology</i> , 2014, 176, 1126-1128.	0.8	11
308	Saphenous Vein Graft Failure After Coronary Artery Bypass Surgery. <i>Circulation</i> , 2014, 130, 1445-1451.	1.6	181
309	Amiodarone, Anticoagulation, and Clinical Events in Patients With Atrial Fibrillation. <i>Journal of the American College of Cardiology</i> , 2014, 64, 1541-1550.	1.2	84
310	Outcomes of a Pharmacoinvasive Strategy for Successful Versus Failed Fibrinolysis and Primary Percutaneous Intervention in Acute Myocardial Infarction (from the Strategic Reperfusion Early) Tj ETQq0 0 0 rgBT (Overlock 14 Tf 50 63	1.0	14
311	Response to the Letter to the Editor titled "Atrial fibrillation in patients with acute coronary syndromes": <i>International Journal of Cardiology</i> , 2014, 171, e106.	0.8	0
312	Impact of Extracardiac Vascular Disease on Vein Graft Failure and Outcomes After Coronary Artery Bypass Surgery. <i>Annals of Thoracic Surgery</i> , 2014, 97, 824-830.	0.7	13
313	Surgical Revascularization Is Associated With Maximal Survival in Patients With Ischemic Mitral Regurgitation. <i>Circulation</i> , 2014, 129, 2547-2556.	1.6	84
314	Central venous pressure after coronary artery bypass surgery: Does it predict postoperative mortality or renal failure?. <i>Journal of Critical Care</i> , 2014, 29, 1006-1010.	1.0	57
315	Efficacy and Safety of Apixaban Compared with Warfarin for Stroke Prevention in Patients with Atrial Fibrillation from East Asia: A Subanalysis of the Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation (ARISTOTLE) Trial. <i>American Heart Journal</i> , 2014, 168, 303-309.	1.2	128
316	Management and clinical outcomes in patients treated with apixaban vs warfarin undergoing procedures. <i>Blood</i> , 2014, 124, 3692-3698.	0.6	149
317	An evaluation of the professional, social and demographic profile and quality of life of physicians working at the Prehospital Emergency Medical System (SAMU) in Brazil. <i>Clinics</i> , 2014, 69, 601-607.	0.6	12
318	Abstract 16741: The Cost-Effectiveness of Apixaban versus Warfarin in Patients With Atrial Fibrillation: Insights From the ARISTOTLE Study Group. <i>Circulation</i> , 2014, 130, .	1.6	2
319	Abstract 15473: The Use of Coronary Artery Bypass Grafts in Non-significant Lesions: Is There Harm to Patients?. <i>Circulation</i> , 2014, 130, .	1.6	0
320	Methods of creatine kinase-MB analysis to predict mortality in patients with myocardial infarction treated with reperfusion therapy. <i>Trials</i> , 2013, 14, 123.	0.7	22
321	Highlights from the fifth international symposium of thrombosis and anticoagulation (ISTA V), october 18-19, 2012, Belo Horizonte, Minas Gerais, Brazil. <i>Journal of Thrombosis and Thrombolysis</i> , 2013, 36, 115-130.	1.0	0
322	Methodology of a reevaluation of cardiovascular outcomes in the RECORD trial: Study design and conduct. <i>American Heart Journal</i> , 2013, 166, 208-216.e28.	1.2	23
323	Results of a reevaluation of cardiovascular outcomes in the RECORD trial. <i>American Heart Journal</i> , 2013, 166, 240-249.e1.	1.2	149
324	Left Bundle Branch Block in Non-ST-Segment Elevation Acute Coronary Syndromes. <i>Journal of the American College of Cardiology</i> , 2013, 61, 1461-1463.	1.2	2

#	ARTICLE	IF	CITATIONS
325	Responding to the letter to the editor by Saver. American Heart Journal, 2013, 166, e39.	1.2	0
326	Prevalence and clinical outcomes of undiagnosed diabetes mellitus and prediabetes among patients with high-risk nonâ€“ST-segment elevation acute coronary syndrome. American Heart Journal, 2013, 165, 918-925.e2.	1.2	87
327	Age, treatment, and outcomes in high-risk nonâ€“ST-segment elevation acute coronary syndrome patients: Insights from the EARLY ACS trial. International Journal of Cardiology, 2013, 167, 2580-2587.	0.8	16
328	Apixaban versus warfarin in patients with atrial fibrillation according to prior warfarin use: Results from the Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation trial. American Heart Journal, 2013, 166, 549-558.	1.2	42
329	Incidence, treatment, and outcomes of atrial fibrillation complicating non-ST-segment elevation acute coronary syndromes. International Journal of Cardiology, 2013, 168, 2510-2517.	0.8	18
330	Saphenous vein graft failure and clinical outcomes: Toward a surrogate end point in patients following coronary artery bypass surgery?. American Heart Journal, 2013, 165, 639-643.	1.2	43
331	Heart Failure Complicating Nonâ€“ST-Segment Elevation Acute Coronary Syndrome. JACC: Heart Failure, 2013, 1, 223-229.	1.9	48
332	Efficacy and Safety of Apixaban Compared With Warfarin at Different Levels of Predicted International Normalized Ratio Control for Stroke Prevention in Atrial Fibrillation. Circulation, 2013, 127, 2166-2176.	1.6	196
333	Alternatives to Warfarin for Stroke Prevention in Patients With Nonvalvular Atrial Fibrillation: A Look Back at the State of the Field in 2012. Postgraduate Medicine, 2013, 125, 146-157.	0.9	0
334	Ankle-brachial index as a predictor of coronary disease events in elderly patients submitted to coronary angiography. Clinics, 2013, 68, 1481-1487.	0.6	18
335	Relationship Between Vein Graft Failure and Subsequent Clinical Outcomes After Coronary Artery Bypass Surgery. Circulation, 2012, 125, 749-756.	1.6	143
336	The association of in-hospital major bleeding with short-, intermediate-, and long-term mortality among older patients with non-ST-segment elevation myocardial infarction. European Heart Journal, 2012, 33, 2044-2053.	1.0	71
337	Efficacy and safety of apixaban compared with warfarin according to patient risk of stroke and of bleeding in atrial fibrillation: a secondary analysis of a randomised controlled trial. Lancet, The, 2012, 380, 1749-1758.	6.3	175
338	Antithrombotic therapy for atrial fibrillation and coronary artery disease in older patients. American Heart Journal, 2012, 164, 607-615.	1.2	23
339	Antithrombotic therapy in heparin-induced thrombocytopenia: guidelines translated for the clinician. Journal of Thrombosis and Thrombolysis, 2012, 34, 552-561.	1.0	8
340	Heart Failure Survival Score in Patients With Chagas Disease: Correlation With Functional Variables. Revista Espanola De Cardiologia (English Ed), 2012, 65, 538-543.	0.4	2
341	Atrial Fibrillation and Acute Myocardial Infarction: Antithrombotic Therapy and Outcomes. American Journal of Medicine, 2012, 125, 897-905.	0.6	37
342	Ticagrelor Versus Clopidogrel in Patients With Acute Coronary Syndromes and a History of Stroke or Transient Ischemic Attack. Circulation, 2012, 125, 2914-2921.	1.6	112

#	ARTICLE	IF	CITATIONS
343	Highlights from the IV International Symposium of Thrombosis and Anticoagulation (ISTA), October 20-21, 2011, Salvador, Bahia, Brazil. Journal of Thrombosis and Thrombolysis, 2012, 34, 143-163.	1.0	0
344	In people with atrial fibrillation unsuitable for warfarin, apixaban reduces the risk of stroke compared with aspirin, with no difference in major bleeding. Evidence-Based Medicine, 2011, 16, 187-188.	0.6	0
345	Apixaban versus Warfarin in Patients with Atrial Fibrillation. New England Journal of Medicine, 2011, 365, 981-992.	13.9	7,537
346	Warfarin and acetaminophen interaction: a summary of the evidence and biologic plausibility. Blood, 2011, 118, 6269-6273.	0.6	35
347	Diagnosing Acute Myocardial Infarction in Patients With Left Bundle Branch Block. American Journal of Cardiology, 2011, 108, 782-788.	0.7	49
348	Antiplatelet agents in cardiovascular disease. Journal of Thrombosis and Thrombolysis, 2011, 31, 306-309.	1.0	18
349	Highlights from the III International Symposium of Thrombosis and Anticoagulation (ISTA), October 14-16, 2010, São Paulo, Brazil. Journal of Thrombosis and Thrombolysis, 2011, 32, 242-266.	1.0	2
350	Antithrombotic Therapy Use at Discharge and 1 Year in Patients With Atrial Fibrillation and Acute Stroke. Stroke, 2011, 42, 3477-3483.	1.0	32
351	Antithrombotic Strategy in Non-ST-Segment Elevation Myocardial Infarction Patients Undergoing Percutaneous Coronary Intervention. JACC: Cardiovascular Interventions, 2010, 3, 669-677.	1.1	20
352	Utilização do FAST-Extendido (EFAST-Extended Focused Assessment with Sonography for Trauma) em terapia intensiva. Revista Brasileira De Terapia Intensiva, 2010, 22, 291-299.	0.1	13
353	Apixaban for Reduction In Stroke and Other Thromboembolic Events in Atrial Fibrillation (ARISTOTLE) trial: Design and rationale. American Heart Journal, 2010, 159, 331-339.	1.2	407
354	Warfarin Use and Outcomes in Patients with Atrial Fibrillation Complicating Acute Coronary Syndromes. American Journal of Medicine, 2010, 123, 134-140.	0.6	38
355	Antithrombotic therapy and outcomes of patients with atrial fibrillation following primary percutaneous coronary intervention: results from the APEX-AMI trial. European Heart Journal, 2009, 30, 2019-2028.	1.0	130
356	Endoscopic versus Open Vein-Graft Harvesting in Coronary-Artery Bypass Surgery. New England Journal of Medicine, 2009, 361, 235-244.	13.9	356
357	Antiplatelet Therapy in Older Adults with Non-ST-Segment Elevation Acute Coronary Syndrome: Considering Risks and Benefits. American Journal of Cardiology, 2009, 104, 16C-21C.	0.7	17
358	Six-Month Follow-Up of Patients With In-Hospital Thrombocytopenia During Heparin-Based Anticoagulation (from the Complications After Thrombocytopenia Caused by Heparin [CATCH])	0.0	0
359	Highlights from the I international symposium of thrombosis and anticoagulation in internal medicine, October 23-25, 2008, Sao Paulo, Brazil. Journal of Thrombosis and Thrombolysis, 2009, 28, 106-116.	1.0	2
360	Advanced Age, Antithrombotic Strategy, and Bleeding in Non-ST-Segment Elevation Acute Coronary Syndromes. Journal of the American College of Cardiology, 2009, 53, 1021-1030.	1.2	125

#	ARTICLE	IF	CITATIONS
361	Antithrombotic therapy in atrial fibrillation: guidelines translated for the clinician. Journal of Thrombosis and Thrombolysis, 2008, 26, 167-174.	1.0	14
362	Late-breaking trials summary from the 2008 American College of Cardiology Scientific Sessions, March 29 to April 1, Chicago, IL. American Heart Journal, 2008, 156, 7-12.	1.2	2
363	Outcomes in elderly patients with acute coronary syndromes randomized to enoxaparin vs. unfractionated heparin: results from the SYNERGY trial. European Heart Journal, 2008, 29, 1827-1833.	1.0	36
364	Novel Markers in Patients with Suspected Acute Coronary Syndromes. , 0, , 75-92.		0
365	Duplex ultrasound for surveillance of lower limb revascularisation. The Cochrane Library, 0, , .	1.5	3